Argenx Se · EURONEXT:ARGX
Argenx — Q4 2024 Earnings Presentation
15 slides from Argenx's earnings presentation, Feb 27, 2025
Slide 1: Reaching Patients Through Immunology Innovation: Q4 2024 Financial Results Call
Reaching Patients Through Immunology Innovation 4 Q 2 0 2 4 F I N A N C I A L R E S U L T S C A L L F E B R U A R Y 2 7 , 2 0 2 5
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: 2025 Strategic Priorities
Fuel pipeline growth 2025 Strategic Priorities PFS Launch Expand next wave of innovation 4 New Molecules in Phase 1 3 Reach more patients with VYVGART 10 Phase 3s 10 Phase 2s
Slide 4: VYVGART is Setting a New Standard for Patients
VYVGART is Setting a New Standard for Patients ECI STAGE A 4 Seronegative gMG and Ocular MG registrational trials Growth momentum continued PFS Positive CHMP opinion PDUFA April 10th CIDP switch study Empasiprubart in CIDP Global decisions on approvals ahead for CIDP MG MSE = MG-ADL SCORE of 0 or 1
Slide 5: Advancing Our Pipeline: Phase 3s and Phase 2s
Advancing Our Pipeline 10 Phase 3s and 10 Phase 2s sngMG & oMG IMNM, ASyS, DM TED Sjögren’s Disease ITP Empasiprubart MMN CIDP DM DGF ARGX-119 CMS Ph1b ALS Ph2a SMA PoC Proof-of-Concept studies AMRLN SSc AIE Registrational studies Proof-of-Concept studies Proof-of-Concept studies Registrational stud
Slide 6: 4 INDs Advancing into Phase 1
4 INDs Advancing into Phase 1 Continued Leadership with Broad Immune System Targets ARGX-213 FcRn ARGX-121 IgA ARGX-220 Target Undisclosed ARGX-109 IL-6 Fc-ABDEGTM Potential for monthly dosing Rapid, deep IgA reduction Best-in-class potency NHance® First-in-class sweeper Convenient dosing Prolonged
Slide 7: Product Net Sales: Q4 of $737 million
Product Net Sales: Q4 of $737 million 7 21 0 100 200 300 400 500 600 700 800 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 75 131 173 218 269 329 374 398 478 573 737 China RoW Japan US 7 7 2 14 11 12 1 6 11 12 26 24 31 36 46 49 2 6 8 10 13 15 17 18 2
Slide 8: Q4 2024 Financial Summary and 2025 Financial Guidance
Q4 2024 Financial Summary 2025 Financial Guidance * Alternative Performance Measure (APM): Cash reflects cash, cash equivalents and current financial assets. Refer to the APM statement. $1.5 billion in cash and cash equivalents and $1.9 billion in current financial assets Ended Q4 with cash of $3.4B
Slide 9: Innovation has no value unless it provides meaningful benefit to patients
Innovation has no value unless it provides meaningful benefit to patients 9
Slide 10: Growing VYVGART Leadership in MG
Growing VYVGART Leadership in MG U.S. Addressable MG Patients Total Addressable Market in 2030 Addressable Market at Launch 17K +11K +7K +25K 60K Seronegative Ocular Growth in Biologics Share of Market Path to 60K Addressable Patients Consistent QoQ growth VYVGART has set a high bar 10 Source: argen
Slide 11: Continued Momentum in CIDP
Continued Momentum in CIDP Patients Physicians Payors ~1,000 Patients on Therapy 90% Lives Covered Majority policies favorable 25% New Prescribers Global Expansion Multiple planned launches in 2025 Breadth and depth of prescribersMajority IVIg-experienced 11
Slide 12: Reaching Patients Across the Globe
Reaching Patients Across the Globe EU • Reimbursement complete in 13 countries • CHMP recommendation for PFS in gMG US • CIDP launched with >1,000 patients on treatment as of end of Q4 Japan • CIDP launched with positive early feedback China • Continued expansion with VYVGART and VYVGART Hytrulo VYV
Slide 13: Strong Growth Trajectory to 50K Patients
Wave 2 (2026-2027) Wave 3 (2028-2030)Wave 1: TODAY TED Myositis oMG snMG Sjogren’s gMG CIDP ITP DM MMN CMS CIDP 50K 13 Strong Growth Trajectory to 50K Patients VYVGART Empasiprubart ARGX-119
Slide 14: We are On a Bold Mission
We are On a Bold Mission Humility Innovation Excellence Co-Creation Empowerment 14
Slide 15: Alternative Performance Measure
Alternative Performance Measure In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, Cash, cash equivalents and current financial assets. This value should not be viewed as a substitute for the company’